2 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Metastatic Endometrioid Adenocarcinoma: new trials by email Literature Review of Metastatic Endometrioid Adenocarcinoma trials Research Report on Metastatic Endometrioid Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Copanlisib, Laboratory Biomarker Analysis - Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Completed | NRG Oncology | 11 | 2016-09-16 | 2022-02-15 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 102 | 2013-05-08 | 2025-10-01 |
Carcinoma, Endometrioid (3) · Breast Neoplasms (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Adenocarcinoma (3) · Adnexal Diseases (3) · Carcinoma (3) · Endocrine System Diseases (3) · Endometrial Neoplasms (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Gonadal Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3)
Fulvestrant (1) · cabozantinib (1) · copanlisib (1) · palbociclib (1)
NRG Oncology (1) · National Cancer Institute (NCI) (1) · Pamela Munster (1)
United States (2) · Canada (1)
Alessandro D Santin (1) · Neesha Dhani (1) · Pamela N Munster, MD (1)
N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), U10CA180868 (1), UM1CA186644 (1)